Lv7
3280 积分 2023-10-10 加入
The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
3个月前
已完结
A Phase Ii, Single-Arm Trial Of Neoadjuvant Axitinib Plus Avelumab In Patients With Localized Renal Cell Carcinoma Who Are At High Risk Of Relapse After Nephrectomy (Neoavax)
3个月前
已完结
Concurrent Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer
6个月前
已完结
Clinical importance of the expression of CD4+CD8+ T cells in renal cell carcinoma
6个月前
已完结
First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
6个月前
已完结
Re: First-line Therapy for Advanced Non–Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis
6个月前
已关闭
Systemic therapy for non–clear cell renal cell carcinomas: A systematic review
6个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
6个月前
已完结
Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)
8个月前
已关闭
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia
8个月前
已完结
皖公网安备34019202002308
